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OBJECTIVEdThis study addressed the long-term effect of various diets, particularly low-
carbohydrate high-protein, on renal function on participants with or without type 2 diabetes.
RESEARCH DESIGN AND METHODSdIn the 2-year Dietary Intervention Random-
izedControlledTrial(DIRECT),318participants(age,51years;86%men;BMI,31kg/m
2;mean
estimatedglomerularﬁltrationrate[eGFR],70.5mL/min/1.73m
2;meanurinemicroalbumin-to-
creatinine ratio, 12:12) with serum creatinine ,176 mmol/L (eGFR $30mL/min/1.73 m
2)we r e
randomized to low-fat, Mediterranean, or low-carbohydrate diets. The 2-year compliance was
85%, and the proportion of protein intake signiﬁcantly increased to 22% of energy only in the
low-carbohydrate diet (P , 0.05 vs. low-fat and Mediterranean). We examined changes in
urinarymicroalbuminandeGFR,estimatedbyModiﬁcationofDietinRenalDiseaseandChronic
Kidney Disease Epidemiology Collaboration formulas.
RESULTSdSigniﬁcant(P,0.05withingroups)improvementsineGFRwereachievedinlow-
carbohydrate (+5.3% [95% CI 2.1–8.5]), Mediterranean (+5.2% [3.0–7.4]), and low-fat diets
(+4.0% [0.9–7.1]) with similar magnitude (P . 0.05) across diet groups. The increased eGFR
was at least as prominent in participants with (+6.7%) or without (+4.5%) type 2 diabetes or
those with lower baseline renal function of eGFR ,60 mL/min/1.73 m
2 (+7.1%) versus eGFR
$60 mL/min/1.73m
2(+3.7%).In amultivariable modeladjustedfor age,sex,diet group,type 2
diabetes, use of ACE inhibitors, 2-year weight loss, and change in protein intake (confounders
and univariate predictors), only a decrease in fasting insulin (b = 20.211; P = 0.004) and systolic
blood pressure (b = 20.25; P , 0.001) were independently associated with increased eGFR. The
urine microalbumin-to-creatinine ratio improved similarly across the diets, particularly among
participantswithbaselinesex-adjustedmicroalbuminuria,withameanchangeof224.8(P,0.05).
CONCLUSIONSdA low-carbohydrate diet is as safe as Mediterranean or low-fat diets in
preserving/improving renal function among moderately obese participants with or without type
2 diabetes, with baseline serum creatinine ,176 mmol/L. Potential improvement is likely to be
mediated by weight loss–induced improvements in insulin sensitivity and blood pressure.
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I
n recent years, growing evidence has
linked obesity with progression of
kidney disease (1,2) as assessed by de-
teriorating glomerular ﬁltration rate
(GFR) or microalbuminuria. Microalbu-
minuria has been identiﬁed as an early
marker of chronic kidney disease (CKD)
and as a predictor of progression to end-
stage kidney disease (3). Moreover, CKD
manifesting with microalbuminuria is an
independentriskfactorformorbidityand
mortality from cardiovascular diseases,
diabetes, and hypertension (4,5).
There is a graded association between
theseverityofobesityandthemagnitudeof
microalbuminuria (6,7). Surgical weight
loss can normalize glomerular hyperﬁltra-
tion and the albumin excretion rate in se-
verely obese patients (8), and dietary
weight loss trials show beneﬁts on albu-
minuria, proteinuria, and the decline in
the estimated GFR (eGFR) in patients
with pre-existing CKD. A review and
meta-analysis of 13 studies, including 2
randomized trials, reported that nonsurgi-
cal weight loss interventions reduce pro-
teinuria and blood pressure and seem to
prevent further decline in renal function
(9,10). However, most of the studies were
relatively small and duration of follow-up
short (typically not exceeding 12 months).
Different dietary strategies to promote
weightlosshavenotdirectlybeencompared
inarandomized,long-term study.This is
especially pertinent to low-carbohydrate
high-protein diets that are debated for
potentially adversely affecting kidney
function, especially among patients with
diabetes(11,12).Arecentstudyamongobese
individuals showed that a low-carbohydrate
high-protein weight loss diet was not
associated with harmful effects on GFR
and albuminuria compared with a low-fat
diet (13).
We therefore investigated the long-
term effect of low-fat, Mediterranean, and
low-carbohydrate dietary intervention
strategies on renal function among over-
weight or obese people with or without
type 2 diabetes and pre-existing mild to
moderaterenaldysfunctionintheDietary
Intervention Randomized Controlled
Trial (DIRECT) (14).
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
The 2-year DIRECT
The DIRECT, previously described in
detail (14), was conducted between July
2005 and June 2007 in Dimona, Israel,
in a workplace at a research center with
an on-site medical clinic. The trial as-
sessed long-term weight loss and various
health parameters among 322 partici-
pants randomized to one of three diets:
low-fat,restricted-calorie;Mediterranean,
restricted-calorie; or low-carbohydrate,
non–restricted-calorie.
Eligible participants were men and
women aged 40–65 years with a BMI
$27 kg/m
2. Individuals with type 2 dia-
betes or coronary heart disease were eligi-
ble regardless of age or BMI. Excluded
were pregnant or lactating women and
participants with a serum creatinine
$176 mmol/L ($2 mg/dL), liver dysfunc-
tion (twofold or higher of the upper limit
of normal in alanine aminotransferase or
aspartate aminotransferase), intestinal
problems that would prevent adherence
to any of the test diets, or active cancer.
Participants were randomized by strata of
sex, age (older or younger than the me-
dian), BMI (below or above the median),
history of coronary heart disease (yes/no),
type 2 diabetes (yes/no), and current use
of statins (none, ,1 year, $1 year).
The overall rate of adherence to the
DIRECT was 95.4% at 1 year and 84.6%
at 2 years, with a total weight loss of 24.0
kg 6 5.6 after 2 years. After 2 years, only
the low-carbohydrate group signiﬁcantly
increased the protein proportion intake
(22% of energy vs. 19% in the low-fat
and Mediterranean diets, P , 0.05), fat,
and dietary cholesterol, signiﬁcantly de-
creasedtheamountofcarbohydrates,and
had thehighest percentage ofparticipants
withdetectableurinaryketones(P,0.05
for all).
The participants received no ﬁnancial
compensation or gifts. The study was
approved and monitored by the Human
Subjects Committee of Soroka Medical
Centre and Ben-Gurion University. The
study was registered at the ClinicalTrials.
gov site (http://clinicaltrials.gov), No.
NCT00160108.
Blood, urine, and clinical
measurements
Blood biomarkers were analyzed in
Leipzig University Laboratories, Leipzig,
Germany. A blood sample was drawn by
venipunctureat8:00 A.M.,aftera12-hfast,
at baseline, and at 6 and 24 months and
stored at 2808C. Spot urinary creatinine
(CREP2, Roche, Germany) and albumin
(ALBT2, Tinaquant, Roche, Germany)
were measured with enzymatic assays us-
ing the automated Roche/Hitachi Cobas
System (Roche, Germany). Plasma insu-
lin, serum high-sensitive C-reactive pro-
t e i n ,t o t a l ,H D L - ,a n dL D L - c h o l e s t e r o l ,
triglycerides, leptin, and total high-
molecular-weight adiponectin, apolipo-
protein A1 (apoA1), and apoB100 were
measured as described previously (13,15).
Body weight was measured to the nearest
0.1 kg every month without shoes. Height
was measured to the nearest millimeter
withtheuseofawall-mountedstadiometer
at baseline for BMI determination. Blood
pressure was measured every 3 months
withthe use ofthe DatascopAcutor 4 auto-
mated system after 5 min of rest.
Statistical analysis
We limited our eGFR analysis to 318
participantsbecauseofmissingeGFRdata
in 4 subjects. We calculated eGFR, ac-
cording to the Modiﬁcation of Diet in
Renal Disease (MDRD) equation (16,17):
[175 3 (serum creatinine)
21.154 3
(age)
20.2033(0.742iffemale)]andaccord-
ingtotheChronicKidneyDiseaseEpidemi-
ology Collaboration (CKD-EPI) equation
(18) [141 3 min(serum creatinine/k,1 )
a 3
max(serum creatinine/k,1 )
21.209 3
0.993
Age 3 1.018 (if female)], where k is
0.7 for females and 0.9 for males, a is
20.329 for females and 20.411 for males,
min indicates the minimum of serum
creatinine/k or 1, and max indicates the
maximum of serum creatinine /k or 1.
Wedichotomizedthestudypopulationac-
cording to baseline eGFR levels (above or
below 60 mL/min/1.73 m
2,e G F Rr a n g ea t
baseline 30–151 mL/min/1.73 m
2). Uni-
variate correlation analysis was used to
evaluate the associations between changes
in eGFR and changes in blood biomarkers
and clinical measurements after 2 years.
The paired t test was used to evaluate
changesineGFRthroughouttheintervention.
We further cross-classiﬁed our popu-
lation by randomized diet group and CKD
stage and further by diabetes status and
performed a similar analysis, as described
above. We performed a multivariable re-
gression analysis to identify predictors of
change in eGFR, including in the model
age, sex, diet group, diabetes status, and
use of ACE inhibitors and the univariate
signiﬁcant predictors of changes in insulin
and blood pressure. We calculated the
urine albumin-to-creatinine ratio to assess
changes in microalbuminuria after 2 years
ofdietaryinterventionbecausetheprotein-
to-creatinine ratio in a random urine spec-
imen provides evidence of the presence of
signiﬁcant proteinuria (19). We deﬁned
microalbuminuria as a urine albumin-to-
creatinine ratio .25 for women or .17
for men (20,21) and also evaluated this ra-
tioasacontinuousvariable.Weperformed
univariate analysis to evaluate the associ-
ations between changes in the albumin-
to-creatinine ratio and changes in blood
biomarkers, clinical measurements, and
dietary assignment among those with or
without microalbuminuria at baseline.
A multivariable model, adjusted for
age,sex,dietgroup,diabetesstatus,useof
ACE inhibitors, 2-year weight loss, de-
crease in fasting insulin level, blood pres-
sure, and 2-year change in saturated fat
was performed to evaluate the indepen-
dent diet-induced changes in microalbu-
minuria.Dataanalysisispresentedforthe
MDRD and CKD-EPI equations.
SPSS 19 software was used for all
statistical analyses. P , 0.05 denoted sta-
tistical signiﬁcance. Values reported are
means 6 SDs, unless otherwise stated.
Multiplelinearregressionresultsarereported
with the parameter estimate and P value for
each variable.
RESULTSdThe DIRECT participants at
baseline (age, 51 years; 86% men; BMI, 31
kg/m
2;meaneGFR,70.5mL/min/1.73m
2;
meanurinemicroalbumin-to-creatininera-
tio, 12.12) had similar distribution of se-
rum creatinine and urine biomarkers, as
well as demographic and clinical charac-
t e r i s t i c sa c r o s st h et h r e ea s s i g n e dd i e t
groups(SupplementaryTable1).Atbase-
line (Table 1), 31% of the participants
had eGFR of 30 to #60 mL/min/1.73 m
2,
deﬁned as CKD stage III (moderate), and
were distributed similarly across the three
diets.Comparedwiththeparticipantswith
CKD stage I/II, those with CKD stage III
wereolder,hadahigherproportionofmen,
had lower levels of adiponectin, apoA1,
and leptin, and were less likely to use
ACE inhibitors and statins (P , 0.05 be-
tween groups for all).
Two-year changes of eGFR
Dietary intervention resulted in a signif-
icant increase in eGFR, regardless of the
dietary strategy: the low-carbohydrate
diet (DeGFR +5.3% [95% CI 2.1–8.5])
was as effective as the Mediterranean
(DeGFR +5.2% [3.0–7.4] or low-fat diets
(DeGFR +4.0%[0.9–7.1],P ,0.05forall
compared with baseline), with similar
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Renal function after weight loss dietsmagnitude (P . 0.05) of effect across the
diet groups (Fig. 1A). Dietary interven-
tion resulted in a signiﬁcant increase in
eGFR, regardless of the dietary strategy:
the low-carbohydrate diet (DeGFR
+1.6%; P = 0.004) was as effective as the
Mediterranean (DeGFR +1.8%; P ,
0.001) or low-fat diets (DeGFR +0.4%;
P = 0.09), with similar magnitude (P .
0.05) of effect across the diet groups; im-
portantly, this apparent improvement in
renal function was not blunted in sub-
groupswithpre-existingconditions,indi-
cating renal dysfunction or high risk for
deterioration of renal function.
Pre-existing moderate CKD. Two years
ofdietaryinterventionwereassociatedwith
an increase in eGFR among participants
with moderate CKD stage III (DeGFR
+7.1 6 3.66% [95% CI 3.4–10.9], P ,
0.05 compared with baseline). This effect
was at least as prominent as in those with
CKD I/II (DeGFR +3.7 6 2.61% [2.1–
5.4], P , 0.05 compared with baseline
and P = 0.055 between groups; Fig. 1B).
When further cross-classiﬁed by diet and
CKD stage (Fig. 1C and D), participants
withCKDstageIIIonthelow-carbohydrate
diet increased eGFR signiﬁcantly by 10%
(P=0.012comparedwithbaseline),those
on the Mediterranean diet by 6% (P =
0.002comparedwithbaseline),andthose
on the low-fat diet by a nonsigniﬁcant
5.4% (P = 0.190).
Two years of dietary intervention were
associatedwithanincreaseineGFRamong
persons with moderate CKD stage III
(DeGFR +2.6%, P = 0.001 compared with
baseline). This effect was at least as prom-
i n e n ta si nt h o s ew i t hC K DI / I I( DGFR
+1.1%, P , 0.001 compared with baseline
and P = 0.33 between groups). When fur-
ther cross-classiﬁedbydietandCKDstage,
participantswithCKDstageIII onthelow-
carbohydrate diet increased eGFR signiﬁ-
cantly by +2.9% (P = 0.18 compared with
baseline), those on the Mediterranean diet
by +2.1% (P = 0.05 compared with base-
line), and those on the low-fat diet by a
nonsigniﬁcant +2.9% (P =0 . 0 1 ) .
Pre-existing type 2 diabetes.P a t i e n t s
with type 2 diabetes (n = 45), who re-
duced 3.5 6 5 . 7k ga f t e r2y e a r so fi n t e r -
vention, signiﬁcantly improved (Fig. 1E)
their eGFR by +6.7% (95% CI 3.0–0.4),
Table 1dBaseline characteristics of the DIRECT study population according to baseline CKD stage
Baseline characteristics
CKD stage III (moderate) CKD stages I and II (normal/mild)
eGFR $30 to #60 mL/min/1.73 m
2 eGFR $60 mL/min/1.73 m
2
n =9 9 n =2 1 9
eGFR (mL/min/1.73 m
2)5 2 . 6 6 5.9 78.6 6 15.8*
Assignment to dietary intervention group (%)
Low-fat 34 31
Mediterranean 36 33
Low-carbohydrate 29 36
Age (years) 52.5 6 6.2 50.5 6 6.3*
Men (%) 99 80*
Current smoker (%) 11.1 18.3
Weight (kg) 93.0 6 13.2 90.6 6 13.5
BMI (kg/m
2)3 0 . 9 6 3.4 30.9 6 3.7
Blood pressure (mmHg)
Systolic 131.5 6 13.9 130.3 6 14.4
Diastolic 79.0 6 8.5 79.4 6 9.1
Waist circumference (cm) 107.6 6 10.9 105.7 6 10.1
Type 2 diabetes, n (%) 17 (17.2) 28 (12.8)
Coronary heart disease, n (%) 31 (31.3) 84 (38.4)
Use of statins, n (%) 15 (15.2) 56 (25.6)*
Use of ACE inhibitors, n (%) 10 (10.1) 42 (19.2)*
Blood biomarkers
Serum cholesterol (mmol/L [mg/dL])
LDL 3.02 6 0.98 (116.8 6 37.8) 3.11 6 0.87 (120.2 6 33.6)
HDL 0.95 6 0.21 (36.9 6 8.1) 1.01 6 0.25† (39.0 6 9.6)†
Serum triglycerides (mmol/L [mg/dL]) 2.01 6 1.09 (178.4 6 96.7) 1.89 6 0.93 (167.2 6 82.8)
ApoB100 (g/L) 0.84 6 0.20 0.85 6 0.18
ApoA1 (g/L) 1.32 6 0.18 1.38 6 0.21*
Plasma HMW adiponectin (mg/dL) 6.6 6 2.2 7.6 6 3.0*
Plasma leptin (mg/dL) 9.7 6 5.7 13.7 6 11.8†
Fasting plasma insulin (pmol/L [mU/mL]) 102.79 6 59.03 (14.8 6 8.5) 94.45 6 59.03 (13.6 6 8.5)
Fasting plasma glucose (mmol/L [mg/dL]) 5.16 6 1.90 (92.9 6 34.2) 5.00 6 1.63 (90.1 6 29.4)
HOMA-IR‡ 3.42 6 2.2 3.13 6 2.7
Urine biomarkers
Albumin (mg/L) 25.7 6 66.1 13.6 6 30.0
Creatinine (mmol/L) 13,500.7 6 7,014.7 15,068.2 6 6,870.9
Microalbumin-to-creatinine ratio 18.0 6 48.7 9.7 6 27.1
Values are means 6 SD or as indicated. The MDRD equation was used to calculate eGFR. HMW, high-molecular-weight. *P =0 . 0 5 .†P = 0.01 between the CKD
groups. ‡HOMA-IR (29): [insulin (units/mL) 3 fasting glucose (mmol/L)/22.5].
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Tirosh and AssociatesFigure 1dA:Two-yearchanges ofeGFR within baseline stages for CKD stage III (black line,eGFR #60 mL/min/1.73 m
2,moderate to severe) and
CKD stages I/II (dashed line, eGFR .60 mL/min/1.73 m
2; mild to normal). *P , 0.05 for improvement withingroups after 2 years of intervention.
B: Two-year changes in eGFR across dietary intervention groups receiving low-fat diet (black line), Mediterranean diet (gray line) and low-
carbohydrate diet (dashed line). *P , 0.05 for improvement within groups after 2 years of intervention. Two-year changes of eGFR across dietary
intervention groups and CKD stage for eGFR .60 mL/min/1.73 m
2 (CKD stage I/II) (C), and eGFR ,60 mL/min/1.73 m
2 (CKD stage III) (D)f o r
patientsreceivingalow-fatdiet(blackline),Mediterraneandiet(grayline),andalow-carbohydratediet(dashedline).*P,0.05forimprovement
withingroupsafter2yearsofntervention.E:Two-yearchanges of eGFR across diabetes status for thosewith (black line)and without (dashedline)
type 2 diabetes. *P , 0.05 for improvement within groups after 2 years of intervention.
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Renal function after weight loss dietssimilar to the +4.5% (2.7–6.3) improve-
ment for participants without diabetes
(P,0.05forallcomparedwithbaseline),
regardless of dietary intervention group.
The eGFR signiﬁcantly improved in
patientswithtype2diabetesby+2.2%(P=
0.003), similar to a +1.1% (P , 0.001) im-
provement in participants without diabetes.
Predictors for 2-year improvement
in eGFR
Inaunivariatecorrelationanalysis,2-year
increase in eGFR was signiﬁcantly associ-
ated with 2-year decrease of body weight,
fasting plasma insulin levels, homeostasis
model assessment of insulin resistance
(HOMA-IR), and systolic and diastolic
blood pressure (P , 0.05 for all). No as-
sociation was found with age, diabetes
status, diet group, or 2-year changes in
speciﬁc macronutrients. A multivariable
model (Table 2) adjusted for age, sex,
diet group, diabetes status, use of ACE
inhibitor medications, 2-year weight
loss, and 2-year change in protein intake
found only a decrease of fasting plasma
insulin (b = 20.211, P = 0.004) and a de-
crease in systolic blood pressure (b =
20.25, P , 0.001) were associated with
increased eGFR.Whenwe used the CKD-
EPI equation (18) for estimating the
eGFR, we received similar signiﬁcant re-
sults. In a multivariable model adjusted
for age, sex, diet group, diabetes status,
usage of ACE inhibitor medications,
2-year weight loss and 2-year change in
protein intake, only a decrease of fasting
plasma insulin (b = 20.186, P = 0.008)
and a decrease in systolic blood pressure
(b = 20.195, P = 0.006) were associated
with increased eGFR when calculated by
CKD-EPI equation.
Two-year changes of urine albumin
and creatinine
Among the 23 participants who met the
criteria for microalbuminuria at baseline,
sex-adjusted levels of urinary albumin
and creatinine decreased after 2 years
(mean 224.8 6 51.6 mg/L, P , 0.05;
Fig. 2). This decrease was 237.9 and sig-
niﬁcantly borderline only in the low-
carbohydrate group (P =0 . 0 7 9 ) ,20.2
in the Mediterranean group (P = 0.993),
and 252.7 in the low-fat diet (P =0.270).
Among the 299 participants without mi-
croalbuminuria at baseline, the urinary
albumin-to-creatinineratiodidnotsignif-
icantly alter. Overall, only 4 of the 23 re-
mained microalbuminuric after 2 years of
intervention (82.6% cure), whereas 7 of
299 participants who did not have base-
line microalbuminuria progressed to hav-
ing microalbuminuria after 2 years (2.3%
progression).
Predictors for 2-year improvement
in urine albumin-to-creatinine ratio
In a univariate correlation analysis, the
2-year decrease in the urinary albumin
and creatinine level was signiﬁcantly as-
sociated with the 2-year decrease of fast-
ing insulin levels and HOMA-IR, as well
as with higher baseline levels of urine mi-
croalbumin (P , 0.05 for all). The 2-year
decreaseintheurinealbumin-to-creatinine
ratiodirectlycorrelatedwiththedecreaseof
the saturated fat level (P = 0.054). Noasso-
ciationwasfoundwithage,diabetesstatus,
diet group, 2-year weight loss, or changes
in protein intake. In a multivariable model
(datanot shown) adjustedfor age,sex,diet
group,diabetesstatus,useofACEinhibitor
medications, 2-year weight loss, decrease
in fasting insulin, blood pressure, and the
2-year change in saturated fat, only higher
baseline levels of urinary microalbumin
(b = 20.793, P , 0.001) remained the in-
dependent predictor for successful diet-
inducedimprovementinmicroalbuminuria.
CONCLUSIONSdIn this study, we
describe the renal outcome in a relatively
large, long-term randomized controlled
trial in which low-carbohydrate, Mediter-
ranean, and low-fat diets were used to
induce weight loss in obese and over-
weight subjects with or without type 2
diabetes and serum creatinine of #176
mmol/L. The low-carbohydrate diet was
at least as effective as the Mediterranean
or low-fat diets in improving eGFR, an
effect likely mediated in all three diets
by the weight loss-induced improvement
in blood pressure and in insulin sensitiv-
ity. Remarkably, this trend of apparent
improvement in renal functions was not
attenuated, andindeedtended tobemore
pronounced, in participants with pre-
existing (baseline) conditions indicating
diminished renal function or being at
high risk for deterioration of renal func-
tion; namely, lower baseline eGFR, type 2
diabetes, and microalbuminuria.
Several limitations of our study war-
rant consideration. Few women were
enrolled in the study, thus compromising
our ability to identify sex-speciﬁcr i s k
factorsintheeffectsofthevariousdietson
kidney function, although there seemed
to be similar weight loss-induced im-
provements in eGFR and microalbumi-
nuria in men and women (data not
shown). In addition, although the sub-
groups of patients with diabetes and
advanced renal impairment are of great
interest to assess the effects of weight loss
diets on kidney function, most of our
participants were not diabetic and had
relatively conserved kidney function. In
particular,only23hadmicroalbuminuria
at baseline. Use of this relatively healthy
population could have potentially led to
underestimation of the beneﬁcial effect of
weight loss on kidney function in the
most vulnerable groups. Nevertheless, a
signiﬁcant improvement in eGFR could
still be observed in addition to robust
regression of microalbuminuria, thus un-
derscoring the importance of weight loss
on slowing the progression, and perhaps
evenregressing,CKDatearlystagesofthe
disease in patients with and without di-
abetes.
Furthermore, another consideration
is that all estimating equations for GFR,
including the MDRD Study equation,
Table 2dFactors associated with 2-year increase in eGFR from a multivariable
regression model
Variables in the model to predict
2-year change of eGFR Standardized coefﬁcients b P value
Age 20.063 0.35
Assigned diet group 20.084 0.22
Male sex 0.019 0.77
Prevalence of type 2 diabetes 0.077 0.25
Use of ACE inhibitors 0.037 0.58
2-year changes
In fasting insulin 20.211 0.004
In weight 20.022 0.76
In systolic blood pressure 20.250 ,0.001
In dietary protein 0.004 0.95
The bold entries indicate statistical signiﬁcance.
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patients with obesity. In fact, it has been
argued that GFR estimates in obese peo-
ple should be indexed to body surface
area (22). Moreover, MDRD may be less
accurate than CKD-EPI in the normaland
slightly increased range of serum creati-
nine concentrations (,133 mol/L [1.5
mg/dL]), which is the relevant range for
detecting CKD (,60 mL/min/1.73 m
2)
(23). Therefore, we analyzed and pre-
sented the data also with the CKD-EPI
equation,whichresultedinsimilarlysig-
niﬁcant ﬁndings.
Use of the calculated eGFR and spot
urinemicroalbuminuria(ratherthana24-h
urinecollection) is a limitation. Further-
more, we used single spot urine at each
timepoint,althoughtheKidneyDisease:
Improving Global Outcomes (KDIGO)
recommends conﬁrmation of albumin-
uriaintwoofthreespoturinecollections
because of intraindividual day-to-day
variation.
C h a n g e si nm u s c l em a s sc a na f f e c t
creatininelevels,thusaffectingeGFRand/
or the albumin-to-creatinine urine ratio,
so changes in fat-free mass may poten-
tially confound results that suggest im-
proved renal function, though probably
in opposite directions. After 2 years,
however, nearly all participants had sta-
bilized weight or tended to exhibit slight
weight regain, which is not consistent
with muscle breakdown.
The strengths of the study include the
one-phase design, in which all participants
started simultaneously, the relatively long
duration of the study, the large size, the
equal intensity of the intervention while
achieving three signiﬁcantly distinct diet
patterns, the high adherence rate, and the
repeated comprehensive measurements of
creatinine, eGFR, and microalbumin and
creatinine throughout the follow-up pe-
riod. The latter allows us to determine that
patients with type 2 diabetes exhibit a
continuousimprovementineGFR(from
baseline to 6 months and from 6 to 24
months) despite a signiﬁcant degree of
weight regain in the latter phase of the
study,whichmayrepresenteffectsofthe
dietary intervention on kidney function
independent of body weight.
Low-protein diets have been pro-
posed to patients with CKD for more
than 50 years. However, the effects of
these diets in preventing severe kidney
failure and the need for maintenance
dialysis have not been resolved. A recent
Cochrane review (24) showed reducing
protein intake in patients with CKD re-
duces the occurrence of renal death by
32% compared with higher or unre-
stricted protein intake. To avoid 1 renal
death, 2–56 patients need to be treated
with a low-protein diet during 1 year. The
optimallevelofproteinintakecouldnotbe
conﬁrmed from these studies, however.
Extrapolatingtheeffectsofmacronutrients,
andespeciallyprotein,onthedeterioration
of kidney function from studies in patients
with CKD to obese people is not obvious.
Most of the participants included in those
studies have already had advanced kidney
disease, and the effects cannot be gener-
alized to those with early subclinical loss
of renal function. Our ﬁndings are con-
sistent with results from a recently pub-
lished small randomized trial of 68
participants with a shorter follow-up pe-
riod of 1 year and with another recently
published randomized trial with rela-
tively low adherence demonstrating
that a very low-carbohydrate diet did
not adversely affect renal function com-
p a r e dw i t hah i g h - c a r b o h y d r a t ed i e ti n
healthy obese individuals (13,25). Other
studies were also consistent with lack of
renal adverse effects during weight loss
with relatively high protein–containing
diets (26,27).
Forpatientswithdiabetes,thewariness
regarding use of high-protein diets is even
greater, because dietary protein restric-
tionwasshowntoslowtheprogressionof
nephropathy in patients with type 1 di-
abetes(28)andtheriskofend-stagerenal
disease (29,30). Similar observations were
conﬁrmedinameta-analysisofﬁvestudies
including 108 patients in which dietary
proteinrestriction resulted ina slowerpro-
gression of diabetic nephropathy (31). In
type 2 diabetes, a low protein diet has also
been suggested to improve renal function
among patients with macroalbuminuria, al-
though no beneﬁt could be documented
among patients with normal renal function
or with microalbuminuria (32).
Several studies have provided evi-
dence that the source of the dietary pro-
tein may be more important for renal
function than the absolute amount of
protein consumed. For example, replac-
ing red meat with chicken in the usual
diet reduced urinary albumin excretion
by 46% in patients with type 2 diabetes
with microalbuminuria (33) or macroal-
buminuria(34).Moreover,adietincluding
a high amount of ﬁsh protein, consump-
tion of which was encouraged in our inter-
ventional trial, provided protection from
the development of diabetic nephropathy
(31,35). Some of the differences observed
betweenthevarioussourcesofdietarypro-
teins have been attributed to different
proportions of saturated versus polyunsat-
urated fat in meat, chicken, and ﬁsh.
Ahighercontentof polyunsaturatedfatty
acidswasreportedtohavebeneﬁcialeffects
on endothelial function (36) that could re-
duce albuminuria and renal injury.
Moreover, weight loss per se may
improve kidney function indirectly by
its effects on blood pressure, glycemia,
andlipidproﬁle,whichmayoutweighthe
Figure 2dTwo-year changes in albumin-to-creatinine ratio across microalbuminuria at base-
line. The urine albumin-to-creatinine ratio was $17 for men and $25 for women. (No micro-
albuminuria,n=299;microalbuminuria,n=23).-=baseline,,=after2yearsofintervention.
*P , 0.05 for improvement within groups after 2 years of intervention. †P , 0.05 for im-
provement between groups after 2 years of intervention.
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etary macro- or micronutrients. Therefore,
the beneﬁcial effects of Mediterranean and
low-carbohydrate diets on insulin sensitiv-
ity and lipid proﬁle, respectively (13), and
the lack of inferiority in improving kidney
functionandregressionofmicroalbuminu-
ria compared with the low-fat diet, suggest
that these diets could be an alternative di-
etary approach for overweight and obese
people with mild renal dysfunction and/
or type 2 diabetes.
We found a strong association be-
tween a decrease in systolic blood pres-
sure and fasting insulin level with
improvement in eGFR and regression of
microalbuminuria. Elevated blood pres-
sure is a well-characterized risk factor for
kidney damage and microalbuminuria
(37), as well as hyperinsulinemia, which
is strongly correlated with the develop-
ment of microalbuminuria early in the
courseofmetabolicsyndromeanddiabetes,
independent of glucose levels (38,39). In
an experimental model in mice lacking
the gene for the melanocortin-4 receptor,
the relative contribution of hyperinsuline-
mia and hypertension to the development
of renal dysfunction could be differenti-
ated. These mice were hyperinsulinemic
butnormotensive(40),yet developedglo-
merular hyperﬁltration and albuminuria.
When hypertension was induced, their
GFR and albuminuria further increased
signiﬁcantly. These data support the con-
cept of an additive or even synergistic ef-
fect of obesity, hyperinsulinemia, and
elevated blood pressure on glomerular
hemodynamics.
In conclusion, we found that dietary
interventions to reduce weight cause pro-
gressive improvement in eGFR and
marked regression of microalbuminuria
regardless of the dietary approach. In
patients with a pre-existing moderate re-
nal dysfunction and microalbuminuria,
or in patients with type 2 diabetes, a low-
carbohydrate high-protein diet is not in-
ferior to other dietary approaches in
improving kidney function.
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